PTC Therapeutics (NASDAQ:PTCT) Price Target Raised to $77.00

Key Points

• Royal Bank of Canada raised PTC Therapeutics’ price target from $75 to $77 while maintaining a “sector perform” rating, implying 23.4% upside from the stock’s $62.40 price. The broader analyst consensus is “Moderate Buy” with a $95.29 target.
• PTC reported third-quarter revenue of approximately $357.8 million, up 69.6% year over year and above expectations, but posted a GAAP loss of $0.62 per share versus the forecasted $0.14 profit.
• Shares fell 3.2% Friday, while the company’s outlook remains supported by strong Sephience sales and a raised 2026 revenue forecast of $1.29 billion to $1.32 billion. PTC also acquired ST-920, a Fabry disease gene therapy, adding a potential late-stage growth asset.

PTC Therapeutics (NASDAQ:PTCT - Get Free Report) had its price target hoisted by equities research analysts at Royal Bank Of Canada from $75.00 to $77.00 in a note issued to investors on Friday, Benzinga reports. The firm currently has a "sector perform" rating on the biopharmaceutical company's stock. Royal Bank Of Canada's price objective indicates a potential upside of 23.40% from the company's current price.

PTCT has been the topic of several other reports. Zacks Research cut shares of PTC Therapeutics from a "strong-buy" rating to a "hold" rating in a report on Thursday, August 6th. Raymond James Financial set a $106.00 target price on PTC Therapeutics in a research note on Tuesday, October 20th. Leerink Partners assumed coverage on PTC Therapeutics in a report on Monday, September 14th. They set an "outperform" rating and a $98.00 price target for the company. UBS Group assumed coverage on PTC Therapeutics in a research note on Thursday, October 15th. They issued a "buy" rating and a $90.00 price target for the company. Finally, Truist Financial began coverage on PTC Therapeutics in a report on Friday, October 16th. They issued a "hold" rating and a $62.00 price objective on the stock. One analyst has rated the stock with a Strong Buy rating, ten have given a Buy rating, three have issued a Hold rating and two have assigned a Sell rating to the stock. According to data from MarketBeat.com, the company presently has an average rating of "Moderate Buy" and a consensus target price of $95.29.

PTC Therapeutics Trading Down 3.2%

Shares of NASDAQ:PTCT traded down $2.06 on Friday, hitting $62.40. The company had a trading volume of 963,860 shares, compared to its average volume of 1,345,500. PTC Therapeutics has a 1-year low of $58.80 and a 1-year high of $90.87. The stock has a market cap of $5.21 billion, a price-to-earnings ratio of -107.58, a P/E/G ratio of 1.90 and a beta of 0.49. The stock has a 50 day moving average price of $65.57 and a 200 day moving average price of $70.87.

PTC Therapeutics (NASDAQ:PTCT - Get Free Report) last posted its earnings results on Thursday, October 29th. The biopharmaceutical company reported ($0.62) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $0.14 by ($0.76). The firm had revenue of $357.81 million for the quarter, compared to the consensus estimate of $306.43 million. The business's revenue was up 69.6% compared to the same quarter last year. During the same period in the previous year, the company posted $0.20 EPS. Sell-side analysts anticipate that PTC Therapeutics will post 1.19 earnings per share for the current fiscal year.

Insider Buying and Selling

In other news, Director Glenn Steele, Jr. sold 12,000 shares of the company's stock in a transaction on Wednesday, September 30th. The stock was sold at an average price of $65.16, for a total transaction of $781,920.00. Following the completion of the sale, the director directly owned 22,500 shares in the company, valued at approximately $1,466,100. This represents a 34.78% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Matthew Klein sold 10,292 shares of the stock in a transaction on Tuesday, August 4th. The stock was sold at an average price of $68.57, for a total value of $705,722.44. Following the sale, the chief executive officer directly owned 383,868 shares in the company, valued at approximately $26,321,828.76. This trade represents a 2.61% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders sold 77,370 shares of company stock valued at $5,322,261 over the last 90 days. 5.30% of the stock is currently owned by insiders.

Institutional Investors Weigh In On PTC Therapeutics

Large investors have recently bought and sold shares of the company. Rock Springs Capital Management LP boosted its position in shares of PTC Therapeutics by 161.5% during the 1st quarter. Rock Springs Capital Management LP now owns 161,798 shares of the biopharmaceutical company's stock worth $11,023,000 after acquiring an additional 99,919 shares in the last quarter. Parkman Healthcare Partners LLC bought a new stake in shares of PTC Therapeutics during the 2nd quarter valued at approximately $35,539,000. VIRGINIA RETIREMENT SYSTEMS ET Al bought a new position in PTC Therapeutics in the 2nd quarter valued at approximately $2,321,000. Janus Henderson Group PLC increased its holdings in shares of PTC Therapeutics by 48.3% during the first quarter. Janus Henderson Group PLC now owns 7,193,433 shares of the biopharmaceutical company's stock worth $489,997,000 after buying an additional 2,342,101 shares in the last quarter. Finally, The Manufacturers Life Insurance Company acquired a new stake in shares of PTC Therapeutics during the 2nd quarter valued at $36,050,000.

Key PTC Therapeutics News

Here are the key news stories impacting PTC Therapeutics this week:

• Positive Sentiment: PTC reported third-quarter revenue of approximately $358 million, up 69.6% year over year and above the roughly $306 million consensus estimate. Product revenue was $276 million, led by Sephience (sepiapterin), which generated $182 million as U.S. adoption and international expansion continued. PTC Therapeutics Third-Quarter Results
• Positive Sentiment: Management raised its 2026 outlook, now expecting total revenue of $1.29 billion to $1.32 billion and product revenue of $960 million to $990 million. The upgrade signals confidence in Sephience’s commercial momentum and the broader product portfolio. PTC Therapeutics Raises 2026 Outlook
• Positive Sentiment: PTC acquired ST-920, a Fabry disease gene therapy, and expects to complete its Biologics License Application submission in the fourth quarter of 2026. The deal adds a potential late-stage growth asset, although regulatory and development execution remain important risks. PTC Corporate Update
• Negative Sentiment: Reported profitability was mixed. PTC posted a GAAP loss of $0.62 per share, well below the consensus estimate for $0.14 of earnings, even though an adjusted earnings measure cited by Zacks was $0.61 per share and above estimates. The conflicting measures may have contributed to investor caution. PTC Swings to Third-Quarter Loss
• Neutral Sentiment: The earnings call focused on Sephience’s launch trajectory, global expansion, the ST-920 acquisition and the updated 2026 outlook. Investors will likely monitor whether revenue growth translates into sustainable earnings and cash flow. PTC Q3 2026 Earnings Call Transcript

About PTC Therapeutics

PTC Therapeutics, Inc is a biopharmaceutical company focused on discovering, developing and commercializing medicines for rare diseases. Its research programs include small-molecule treatments, gene therapies and other approaches designed to address conditions with limited or no available treatment options.

The company's commercial portfolio has included Emflaza (deflazacort), a corticosteroid approved in the United States to treat Duchenne muscular dystrophy, and Upstaza (eladocagene exuparvovec), a gene therapy authorized in the European Union for aromatic L-amino acid decarboxylase deficiency.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.